Table 1 Clinical characteristics of the glioblastoma population at Brown University Health and their prognostic and treatment-related factors.
From: Medical comorbidities prognosticate survival in glioblastoma
Characteristics (n = 867) | Frequency (%) | Median OS in months (95% CI) | |
|---|---|---|---|
Age (p < 0.0001) | |||
<50 | 98 (11.3%) | 24 (20–28) | |
50–59 | 184 (21.2%) | 17 (15–20) | |
60–69 | 282 (32.6%) | 11 (10–13) | |
70–79 | 195 (22.5%) | 7 (5–9) | |
≥80 | 108 (12.4%) | 3.5 (3–6) | |
Sex (p = 0.6124) | |||
Male | 493 (56.9%) | 11 (10–12) | |
Female | 374 (43.1%) | 11 (10–12) | |
KPS (p < 0.0001) | |||
90–100 | 271 (31.2%) | 18 (16–21) | |
70–80 | 297 (34.2%) | 12 (11–15) | |
50–60 | 218 (25.1%) | 5 (4–7) | |
10–40 | 64 (7.4%) | 2 (1–3) | |
KPS unknown | 17 (2.0%) | ||
Extent of resection (p < 0.0001) | |||
Gross Total | 297 (34.3%) | 16 (15–19) | |
Partial | 278 (32.1%) | 11 (10–13) | |
Biopsy only | 292 (33.7%) | 5 (4–6) | |
Treatment | |||
(p < 0.0001) | Chemo + Radiation | 677 (78.1%) | 14 (13–15) |
No Chemo + Radiation | 190 (21.9%) | 2 (2–3) | |
(p < 0.0001) | Bevacizumab | 262 (30.2%) | 19 (17–21) |
No Bevacizumab | 605 (69.8%) | 8 (7–9) | |
Tumor Markers | |||
(p < 0.0001) | MGMT + | 275 (31.7%) | 17 (13–21) |
MGMT − | 212 (24.5%) | 11 (10–13) | |
MGMT unknown | 380 (48.3%) | ||
(p < 0.0001) | IDH mutant | 10 (1.2%) | 101 (n/a) |
IDH wild-type | 508 (58.5%) | 12 (11–14) | |
IDH unknown | 349 (40.3%) | ||
